Analyst Price Target is $14.83
▲ +89.20% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $14.83, with a high forecast of $21.00 and a low forecast of $10.00. The average price target represents a 89.20% upside from the last price of $7.84.
Current Consensus is
Moderate Buy
The current consensus among 7 contributing investment analysts is to moderate buy stock in Cogent Biosciences. This rating has held steady since November 2023, when it changed from a Buy consensus rating.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More
